BOSTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. The data are being presented this week in late-breaker sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2007), currently taking place in Boston, Massachusetts (November 2-6).
